SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
+14.15%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$80.3M
AUM Growth
+$80.3M
(-4.3%)
Cap. Flow
-$14.2M
Cap. Flow
% of AUM
-17.64%
Top 10 Holdings %
Top 10 Hldgs %
61.84%
Holding
47
New
13
Increased
9
Reduced
9
Closed
11
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$5.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$4.74M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$4.68M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$3.88M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$1.76M |
Top Sells
| 1 |
Zai Lab
ZLAB
|
$5.6M |
| 2 |
Legend Biotech
LEGN
|
$5.44M |
| 3 |
Pfizer
PFE
|
$4.97M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$4.81M |
| 5 |
UroGen Pharma
URGN
|
$4.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cogent Biosciences
COGT
$1.69B
| $6.91M | 8.19% |
962,951
+188,230
| +24% | +$1.35M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $6.52M | 7.73% |
68,982
-27,839
| -29% | -$2.63M |
|
|
3
Neurocrine Biosciences
NBIX
$14B
| $5.1M | 6.04% |
+40,608
| New | +$5.1M |
|
4
Terns Pharmaceuticals
TERN
$641M
| $4.8M | 5.68% |
1,286,681
-70,472
| -5% | -$263K |
|
|
5
Ultragenyx Pharmaceutical
RARE
$3B
| $4.74M | 5.61% |
+130,422
| New | +$4.74M |
|
|
6
Zai Lab
ZLAB
$3.71B
| $4.72M | 5.59% |
134,895
-160,052
| -54% | -$5.6M |
|
|
7
Jazz Pharmaceuticals
JAZZ
$7.89B
| $4.68M | 5.54% |
+44,107
| New | +$4.68M |
|
8
BridgeBio Pharma
BBIO
$10B
| $4.18M | 4.95% |
96,766
-87,156
| -47% | -$3.76M |
|
9
Travere Therapeutics
TVTX
$1.62B
| $4.09M | 4.84% |
276,474
+38,987
| +16% | +$577K |
|
|
10
Ionis Pharmaceuticals
IONS
$8.92B
| $3.88M | 4.6% |
+98,267
| New | +$3.88M |
|
|
11
Oric Pharmaceuticals
ORIC
$996M
| $3.5M | 4.15% |
344,922
-474,272
| -58% | -$4.81M |
|
12
Soleno Therapeutics
SLNO
$3.61B
| $2.82M | 3.34% |
33,691
+14,359
| +74% | +$1.2M |
|
13
Savara
SVRA
$565M
| $2.54M | 3.01% |
1,115,379
+149,176
| +15% | +$340K |
|
14
89bio
ETNB
$1.37B
| $2.09M | 2.47% |
212,377
+103,221
| +95% | +$1.01M |
|
15
Cytokinetics
CYTK
$5.72B
| $2.02M | 2.39% |
61,103
-11,889
| -16% | -$393K |
|
|
BCAX
16
Bicara Therapeutics Inc. Common Stock
BCAX
$641M
| $1.76M | 2.09% |
+189,699
| New | +$1.76M |
|
17
Cabaletta Bio
CABA
$134M
| $1.61M | 1.91% |
1,060,764
+601,792
| +131% | +$915K |
|
|
TECX
18
Tectonic Therapeutic, Inc. Common Stock
TECX
$329M
| $1.57M | 1.86% |
79,058
+28,312
| +56% | +$563K |
|
19
Insmed
INSM
$30.5B
| $1.47M | 1.74% |
+14,571
| New | +$1.47M |
|
20
United Therapeutics
UTHR
$19B
| $1.4M | 1.66% |
+4,874
| New | +$1.4M |
|
21
Avidity Biosciences
RNA
$5.98B
| $1.34M | 1.58% |
47,037
+24,766
| +111% | +$703K |
|
|
22
UroGen Pharma
URGN
$894M
| $1.2M | 1.43% |
87,912
-335,720
| -79% | -$4.6M |
|
23
Protara Therapeutics
TARA
$120M
| $1.09M | 1.29% |
360,000
| – | – |
|
|
ZBIO
24
Zenas BioPharma, Inc. Common Stock
ZBIO
$726M
| $1.08M | 1.28% |
111,605
| – | – |
|
25
Liquidia Corp
LQDA
$2.49B
| $886K | 1.05% |
+71,071
| New | +$886K |
|